ELI LILLY AND COMPANY |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 698.8 EUR | -0.53% |
|
-1.23% | +32.73% |
| Sales 2024 * | 41.36B 38.82B | Sales 2025 * | 51.35B 48.2B | Capitalization | 672B 631B |
|---|---|---|---|---|---|
| Net income 2024 * | 10.89B 10.22B | Net income 2025 * | 15.79B 14.82B | EV / Sales 2024 * | 16.6 x |
| Net Debt 2024 * | 15.19B 14.26B | Net Debt 2025 * | 10.74B 10.08B | EV / Sales 2025 * | 13.3 x |
| P/E ratio 2024 * |
61.4
x | P/E ratio 2025 * |
41.6
x | Employees | 43,000 |
| Yield 2024 * |
0.69% | Yield 2025 * |
0.8% | Free-Float | 99.79% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eli Lilly and Company
More recommendations
More press releases
More news
| 1 day | -0.53% | ||
| 1 week | -1.23% | ||
| Current month | -3.55% | ||
| 1 month | -1.58% | ||
| 3 months | +21.32% | ||
| 6 months | +25.46% | ||
| Current year | +32.73% |
1 week
690.50
720.20
1 month
690.50732.50
Current year
529.00737.00
1 year
335.20737.00
3 years
147.60737.00
5 years
94.66737.00
10 years
41.83737.00
| Managers | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 95-12-31 |
Anat Ashkenazi
DFI | Director of Finance/CFO | 51 | 00-12-31 |
Ruth Gimeno
PSD | President | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 21-01-24 | |
Ralph Alvarez
BRD | Director/Board Member | 67 | 09-03-31 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 04-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 698.8 | -0.54% | 391 |
| 24-04-18 | 702.6 | +0.09% | 246 |
| 24-04-17 | 702 | -0.54% | 249 |
| 24-04-16 | 705.8 | -0.32% | 520 |
| 24-04-15 | 708.1 | +0.08% | 406 |
Delayed Quote Deutsche Boerse AG, April 19, 2024 at 08:11 am EDT
More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
2024-04-30
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
746
USD
Average target price
813.3
USD
Spread / Average Target
+9.03%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +23.35% | 550B | |
| -7.02% | 351B | |
| +14.85% | 317B | |
| +6.25% | 292B | |
| +2.38% | 211B | |
| -0.37% | 203B | |
| -9.94% | 194B | |
| -11.81% | 144B | |
| -8.80% | 141B |
- Stock Market
- Equities
- LLY Stock
- LLY Stock
